合成血静密封剂:有效性,安全性和体内应用
Federica Curcio1, Paolo Perri2, Paolo Piro2
1Department of Pharmacy, Health and Nutritional Science, University of Calabria, Arcavacata, 87036 Rende, Italy.
Pharmaceuticals (Basel, Switzerland)
|March 28, 2024
概括
两种手术密封剂Glubran 2和AristaTMAH在血管外科手术中有效地实现了快速静血. 这两种药物在动脉静脉瘤修复和伪动脉瘤治疗等程序中都显示出安全性和有效性.
科学领域:
- 血管外科 血管外科
- 生物材料是一种生物材料.
- 外科手术静血 静血是什么
背景情况:
- 快速的血液静止在手术中至关重要,以减少手术时间,输血和改善患者的治疗结果.
- 静血剂,密封剂和粘合剂在血管外科手术中具有优势,但其组成,应用和有效性各不相同.
- 通常使用的药物包括基于烯酸的剂 (Glubran 2) 和多糖水凝微球粉 (AristaTMAH).
研究的目的:
- 评估两种不同的静血密封剂Glubran 2和AristaTMAH的安全性和有效性.
- 评估这些密封剂在手术部位促进血液静止的能力.
- 在血管程序中,将密封剂性能与其化学物理特性相关联.
主要方法:
- 追溯性研究,分析血管疾病治疗患者数据.
- 两种静血密封剂的比较:Glubran 2 (?? 烯酸粘合剂) 和AristaTMAH (多糖水凝微球粉).
- 在动脉静脉 (FAV),伪动脉瘤和外围插入中央导管 (PICC) 放置中对密封剂的应用进行评估.
主要成果:
- 格鲁布兰2和阿里斯塔TMAH都被证明是作为外科伤口关闭系统的有效和安全.
- 动脉静脉的成功率包括≥94%的动脉静脉瘤解剖,和≤95%的伪动脉瘤.
- 使用AristaTMAH实现了100%的成功,用于稳定外围插入的中央导管 (PICC) 线路.
结论:
- 格鲁布兰2和AristaTMAH是血管外科手术应用中的有效和安全的止血剂.
- 这些密封剂促进静血过程,在复杂的血管程序中提供可靠的结果.
- 这项研究支持使用这些药物来改善手术关闭伤口和在血管干预中改善患者管理.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
01:05Introduction to Hemostasis
7.6K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.5K